Becton, Dickinson and Company
BDXHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science. The company carries a $54.18B market cap, placing it firmly in the large-cap category. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
Market Cap
$54.18B
Beta
0.28
P/E (TTM)
46.26
P/E (Fwd)
14.95
EPS (TTM)
$4.30
EPS (Fwd)
$13.30
ROE
6.6%
ROA
4.3%
Cash
$709.0M
Total Debt
$16.81B
Free CF
$4.48B
52W Change
35.3%
Annual Financials
Cash vs Debt
Where BDX stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, BDX finished 16.07% above its 150-day moving average ($161.43) and 15.77% above its 200-day moving average ($161.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BDX overbought or oversold?
At the October 14, 2026 close, BDX's RSI(14) was 58.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BDX has $709.0M in cash with $16.81B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $4.48B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 6.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.3% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $18.87B to $21.84B.
The relatively low beta of 0.28 suggests BDX is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing BDX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.